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Abstract
Background: Several lists of potentially inappropriate medication (PIM) for elderly patients have been developed
worldwide in recent years. Those lists intend to reduce prescriptions of drugs that carry an unnecessarily high risk
of adverse drug events in elderly patients. In 2010, an expert panel published the PRISCUS list for the German drug
market. This study calculates the amount of drug reimbursement for PIM in Germany and potential cost effects
from the perspective of statutory health insurance when these are replaced by the substitutes recommended by
the PRISCUS list.
Methods: Register-based data for the 30 top-selling drugs on the PRISCUS list in 2009 for patients greater than or
equal to 65 years of age were provided by the Scientific Institute of the German Local Health Care Fund. We calculated
the percentage of sales and defined daily doses for patients greater than or equal to 65 years of age compared with the
total statutory health insurance population. Reimbursement costs for the recommended substitutions were estimated by
considering different scenarios.
Results: In 2009, drug reimbursement for the 30 top-selling PIM prescribed to patients greater than or equal to 65 years
of age were calculated to be €305.7 million. Prescribing the recommended substitution medication instead of PIM
would lead to an increased total reimbursement cost for the German health care system ranging between from €325.9
million to €810.0 million.
Conclusions: The results show that the substitution of PIM by medication deemed to be more appropriate for the
elderly comes along with additional costs. Consequently, there is no short-term incentive for doing so from a payer
perspective. Future studies have to consider the long-term effects and other sectors.
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Background
Potentially inappropriate medication (PIM) can influence
the safety of elderly patients’ drug therapy. Several inter-
national studies have shown that PIM might lead to
higher morbidity and mortality as well as it contributes
to adverse drug events (ADE) and hospital admissions
[1–3]. Consequently, PIM might have an impact on the
health and quality of life of elderly people. Thus, a need
has emerged for the systematic identification and
description of inadequate pharmacotherapy for older
patients. Different classification systems of critical drugs
have been developed in many countries to support physi-
cians in clinical practice such as the Beers criteria in the US
[4], McLeod in Canada [5], and Laroche in France [6]. The
prevalence of PIM is calculated between 13 % and 43 %, de-
pending on the tool used and the study setting [7, 8].
In Germany, the Federal Ministry of Health initiated an
evaluation of PIM in 2008/2009 considering the country-
specific characteristics of the pharmaceutical market.
Details of the development process have been described
elsewhere [9]. The result was the so-called PRISCUS list,
which comprises 83 agents classified as PIM. Altogether,
64 agents are listed on one or more international PIM
lists, 12 agents are only available in Germany and seven
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are solely classified as PIM in Germany [9]. In contrast to
former frameworks, the PRISCUS list is more than a
listing of critical agents for elderly patients. Additional
information about the adequate substitution of PIM is
provided [9, 10]. Several studies evaluate PIM in Germany
and have determined the prevalence to be between 18 %
and 43 %, depending on the setting and patient group
[11–14]. However, the social and economic burden has
not been addressed so far.
The aim of this investigation was to analyse the reim-
bursement costs of PIM according to the PRISCUS list
and to evaluate the economic effects of a recommended
substitution from the perspective of SHI in Germany. As
the PRISCUS list was explicitly developed for the German
pharmaceutical market, we will use it to detect PIM in the
German SHI population. We provide information about
(a) the proportion of agents on the PRISCUS list pre-
scribed to elderly people ≥65 years of age, (b) the reim-
bursement costs of PIM from the perspective of SHI
and (c) the potential costs of the recommended substi-
tution medication.
Methods
The methodology of the study consists of three components.
First, anonymised medication data on patients ≥65 years of
age were obtained and enriched with information about
the entire SHI population. Second, costs for the pre-
scription of surrogates were calculated based on differ-
ent scenarios. Third, we conducted a literature research
to identify international studies for comparison with
our results.
Data source
The underlying anonymised aggregated prescription data
were provided by the Scientific Institute (WIdO) of the
German Local Health Care Fund (AOK). It was founded
in 1976 and has the function to carry out research projects
aimed at ensuring high quality and economic health care
for the community of the Local Health Care Funds [15].
The WIdO has a prescription register of all drugs pre-
scribed to patients in German SHI, excluding drugs dis-
pensed at hospitals, over-the-counter (OTC) compounds,
and prescriptions of private health insurance. Our study
material is a register extraction of PRISCUS agents solely
given to patients aged ≥65 years in 2009. The WIdO
provided the sales volume, number of prescriptions,
and the prescribed defined daily dose (DDD) for the
top 30 PRISCUS agents with the highest sales volume.
Additionally, the total sales volume, the total number of
prescriptions, and the total amount of DDDs for all 83
agents on the PRISCUS list for the patient group ≥65 years
of age were provided.
The data set was enhanced with additional information
from the pharmaceutical prescription report from 2010
(PPR) [16]. The PPR is an annual publication by the
WIdO about the 3000 most frequently prescribed drugs to
the SHI population in Germany. Therefore, the provided
data set and the enriched data have the same origin. First,
we extracted the sales volume, prescriptions, DDDs, and
costs per DDD of all PRISCUS agents for the entire SHI
population from the PPR. Second, based on the enhanced
data set, we calculated the share of patients ≥65 years of
age in the entire SHI population for sales volume, pre-
scriptions, and DDDs.
Scenarios
To calculate the potential costs of the recommended
drug substitutions, we first derived the costs per DDD
for the recommended surrogates from the PPR. In the
first case, if a specifically drug was named, the costs per
DDD were directly taken from the PPR. In the second
case, if a drug group was recommended as an adequate
alternative, a weighted average based on the costs per
DDD and the prescribed annual DDDs was calculated.
For example, the recommended alternatives on the
PRISCUS list for indometacin are (1) paracetamol, (2)
weak opioids (tramadol and codeine), (3) metamizol
(after careful consideration of the risks and the benefits)
and (4) "weaker" NSAIDs (e.g., ibuprofen) [9]. For (1)
paracetamol and (3) metamizol, the costs per DDD were
taken from the PPR (€0.49/DDD and €1.51/DDD). For (2)
weak opioids, tramadol and codeine are explicitly recom-
mended. Thus, the costs per DDD for these two agents
were also taken from the PPR (€1.19/DDD and €2.65/
DDD). By contrast, for (4) “weaker” NSAIDs, ibuprofen is
only one example of a possible substitution. Thus, the
costs per DDD for the whole group of "weaker" NSAIDs
were calculated (€0.56/DDD).
In a second step, the reimbursement costs for an ad-
justed drug therapy was estimated under the consider-
ation of the recommended surrogate according to the
PRISCUS list. We assumed that the amount of DDDs
for the recommended surrogates would not differ from
the actual prescribed DDDs of PIM. To calculate the
economic impact, the costs per DDD for the proposed
substitution were multiplied by the prescribed amount
of DDDs for patients ≥65 years of age. As several drugs
or drug groups are recommended in some cases, a range
of costs per DDD for surrogates had to be considered.
Thus, we performed three different scenarios. Besides
the cheapest (Scenario 1) and the most expensive surro-
gate (Scenario 2), we also calculated the mean costs per
DDD of the proposed alternatives (Scenario 3) and the
corresponding costs of the prescription.
Literature review
Two systematic literature reviews were conducted to
compare the results with national and international
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studies. The first one consisted of studies dealing with the
prevalence of PIM in Germany measured by applying the
PRISCUS list. The second one focused on international
studies analysing reimbursement costs. We carried out
two Medline searches on the 2nd of November 2014. In
order to identify the prevalence of PIM in Germany, we
combined 18 synonyms for PIM, such as potentially in-
appropriate medication, inappropriate prescribing, and in-
appropriate practice in prescribing with “PRISCUS”. For
the identification of studies of the costs of PIM, we com-
bined the keywords cost OR costs OR cost analysis OR
cost analyses OR drug reimbursement OR drug reim-
bursements OR economic burden OR economic evalu-
ation and elder* OR old* OR geriatric* OR senior OR
aged OR aging with the same words on PIM as in the
search on prevalence. The complete search history for
both searches can be obtained from the first author upon
request. The search was not limited with regard to lan-
guage and timeframe. Identified studies were searched by
reviewing the references as well. For search 1, only studies
of the prevalence of PIM in Germany were included. For
search 2, papers were included if they examined the na-
tionwide costs of PIM on an annual basis. Papers only
examining the prevalence or the applicability of tools to
identify PIM were excluded.
Results
In 2009, the total expenditure for all 83 agents on the
PRISCUS list was €387.8 million and the reimbursement
costs of the 30 top-selling agents amounted to €305.7
million (78.8 %). The highest reimbursement costs were
caused by solifenacin, with €32.5 million, followed by
etoricoxib (€30.6 million), and zopiclone (€21.5 million),
as displayed in Table 1. Those three agents accounted
for approximately 20 % of the total sales volume. Com-
pared with the entire SHI population in Germany, the
total sales for the 30 top-selling agents were €505.5
million and €562.7 million for all 83 agents PRISCUS
agents, respectively. Thus, 54.3 % and 37.4 % of sales
can be assigned to patients ≥65 years of age.
Focusing on the number of PIM prescriptions to the
elderly, there were 13.75 million prescriptions of the 30
top-selling PIM. For all PRISCUS agents, there were
16.93 million prescriptions to the elderly in 2009. Com-
pared with the entire SHI population with 26.15 million
prescriptions of the 30 top-selling PRISCUS agents and
31.71 million prescriptions of all 83 PRISCUS agents,
52.6 % and 44.9 % of the prescriptions were allocated to
the elderly, respectively. Regarding all prescriptions to
the entire SHI population (626.3 million in 2009), the
elderly obtained 56 % (350.7 million) of them [16].
Consequently, the number of PIM prescriptions to the
elderly compared with the total prescriptions to pa-
tients ≥65 years of age was 4.8 %.
The sum of DDDs for the 30 top-selling PRISCUS
agents was 502.9 million DDDs and 598.3 million DDDs
for all 83 agents. The leading agents were doxazosin
(51.4 million DDDs), amitriptyline (45.7 million DDDs),
and sotalol (34.0 million DDDs). In the entire SHI popu-
lation, 864.40 million DDDs of the 30 top-selling PIM
and 1,124.0 million DDDs of all PIM were prescribed.
Thus, the majority of prescribed DDDs of the 30 top-
selling PIM (58.2 %) may be assigned to patients for
whom the drugs are potentially inadequate. Regarding
all PIM on the PRISCUS list, 53.3 % of the DDDs for the
entire SHI population were prescribed to the elderly.
Table 2 shows information on the costs and DDDs for
PIM and the recommended surrogates on the PRISCUS
list. When applying Scenario 1, the reimbursement costs
for the 30 top-selling agents on the PRISCUS list would
be €325.93 million and this would lead to higher total
costs of €20.23 million (+6.6 %). For Scenario 2, the
costs of medication would rise to €810.03 million and
cause additional costs of €504.33 million (+165.0 %). By
applying Scenario 3, the costs for the 30 top-selling
drugs would rise by €124.76 million to €430.46 million
(+40.8 %).
Considering the results for Scenario 1, only 10 sur-
rogates lead to increased reimbursement costs,
whereas the substitution of the remaining 20 agents
leads to a cost decrease. However, these 10 surrogates
increase the costs by +200.0 % on average, whereas
the decrease is -53.3 % on average. The cost driver in
Scenario 1 is memantine (€3.86/DDD), a proposed surro-
gate for piracetam (€0.45/DDD), pentoxifyllin (€0.54/DDD),
and naftidrofuryl (€1.11/DDD). The substitution of these
three agents by memantine causes costs of €70.6 million,
€57.9 million and €29.0 million, respectively. This results in
a potential cost increase of €133.9 million (+467.0 %), from
€23.6 million to €157.5 million.
In Scenario 2, 22 agents increase the costs by +289.0 %
on average. The most cost-intensive surrogates are acety-
cholinesterase inhibitors (€4.25/DDD) – as proposed alter-
natives for piracetam, pentoxifyllin, and naftidrofuryl – and
this would lead to increased reimbursement costs of €173.4
million (+635.0 %), from €23.6 million to €197.0 million.
The other cost drivers in Scenario 2 are the recommended
substitutes for etoricoxib (e.g., lamotrigine, oxcarbazepine,
gabapentin). This substitution would raise reimbursement
costs from €30.6 million to €101.56 million (+232.0 %).
If indomethacin (0.46€/DDD) was substituted by co-
deine (2.65€/DDD), the cost of the medication would
rise by +476.4 %. Only the substitution of eight agents
would lead to a decrease in total reimbursement costs,
by -27.5 %.
Considering the mean surrogate costs in Scenario 3, in
14 cases the substitution of the 30 top-selling agents would
lead to a decrease in reimbursement costs by -37.9 % on
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Table 1 30 top-selling agents on PRISCUS list (Prices in €, Reference year 2009)
Aged 65 and above Entire SHI population Ratio aged ≥65 and entire SHI














Costs per DDD DDD Prescriptions Sales
1 C02CA04 Doxazosin 51.4 0.56 19.5 0.38 € 60.2 0.81 28.1 0.38 € 85.38 % 69.47 % 69.37 %
2 N06AA09 Amitriptyline 45.7 1.13 19.8 0.43 € 94.5 2.28 40.5 0.43 € 48.36 % 49.66 % 48.88 %
3 C07AA07 Sotalol 34.0 0.53 10.2 0.30 € 36.6 0.68 13.0 0.30 € 92.90 % 78.39 % 78.56 %
4 C01AA02 Acetyldigoxin 32.5 0.93 11.7 0.36 € 36.4 1.05 13.3 0.36 € 89.29 % 88.62 % 88.06 %
5 N05CF01 Zopiclona 28.0 1.44 21.5 0.77 € 47.3 2.62 38.7 0.79 € 59.20 % 54.87 % 55.56 %
6 M01AH05 Etoricoxib 25.2 0.50 30.6 1.21 € 51.7 1.07 62.4 1.21 € 48.74 % 46.61 % 49.04 %
7 N06AA12 Doxepin 24.2 0.77 13.1 0.54 € 54.2 1.68 29.1 0.52 € 44.65 % 45.71 % 45.07 %
8 G04BD08 Solifenacin 22.6 0.24 32.5 1.44 € 31.3 0.33 44.8 1.43 € 72.20 % 72.84 % 72.54 %
9 N05CF02 Zolpidema 21.3 1.09 16.3 0.77 € 32.5 1.81 26.7 0.78 € 65.54 % 60.36 % 61.14 %
10 N06BX03 Piracetam 18.3 0.41 8.2 0.45 € 20.6 0.48 9.7 0.45 € 88.83 % 85.85 % 84.86 %
11 C04AD03 Pentoxifylline 15.0 0.35 7.2 0.48 € 17.7 0.57 11.0 0.54 € 84.75 % 61.29 % 65.61 %
12 N05BA08 Bromazepam 14.9 0.66 8.6 0.58 € 21.2 1.04 13.5 0.60 € 70.28 % 63.40 % 63.65 %
13 N06AA06 Trimipramine 14.6 0.49 10.8 0.74 € 31.6 1.12 24.5 0.73 € 46.20 % 43.66 % 44.17 %
14 N05BA01 Diazepam 13.1 0.53 6.0 0.46 € 31.0 1.30 15.3 0.47 € 42.26 % 40.71 % 39.16 %
15 N05CD06 Lormetazepama 12.5 0.38 5.2 0.42 € 15.3 0.51 7.0 0.42 € 81.70 % 74.50 % 74.20 %
16 C02CA08 Terazosin 12.3 0.19 6.6 0.54 € 8.0 0.24 8.2 0.56 € -b - -
17 C02AC01 Clonidine 11.7 0.33 5.9 0.50 € 17.7 0.71 13.5 0.34 € 66.10 % 46.72 % 43.86 %
18 C02LA01 Reserpine and
Diuretics
11.3 0.12 4.7 0.42 € 13.1 0.14 5.5 0.42 € 86.26 % 88.82 % 85.45 %
19 C01BC04 Flecainide 9.7 0.22 11.4 1.18 € 14.1 0.34 17.5 1.17 € 68.79 % 64.05 % 65.30 %
20 G04BD04 Oxybutynin 9.3 0.30 8.8 0.95 € 11.3 0.45 15.1 0.95 € 82.30 % 66.64 % 58.14 %
21 M01AC06 Meloxicam 9.3 0.21 3.3 0.35 € 14.8 0.41 6.3 0.38 € 62.84 % 50.66 % 52.12 %
22 N06AB03 Fluoxetine 8.8 0.10 2.9 0.33 € 43.3 0.58 17.3 0.32 € 20.32 % 17.32 % 16.79 %
23 M01AB01 Indometacin 8.7 0.25 4.0 0.46 € 14.2 0.53 8.6 0.48 € 61.27 % 47.36 % 46.63 %
24 C01AA08 Metildigoxin 8.4 0.17 2.7 0.32 € 9.5 0.20 3.0 0.32 € 88.42 % 86.65 % 90.00 %
25 M03BX07 Tetrazepam 8.3 0.57 8.0 0.96 € 22.0 2.08 26.8 1.19 € 37.73 % 27.46 % 29.90 %
26 C04AX21 Naftidrofuryl 7.5 0.34 8.2 1.09 € 9.0 0.43 10.2 1.11 € 83.33 % 78.49 % 80.17 %
27 C08CA05 Nifedipinea 6.5 0.26 3.8 0.58 € 69.7 1.32 22.2 0.29 € 9.33 % 19.70 % 17.11 %
28 M01AB11 Acemetacin 6.4 0.16 4.9 0.77 € 9.8 0.28 8.3 0.80 € 65.31 % 56.34 % 58.76 %















Table 1 30 top-selling agents on PRISCUS list (Prices in €, Reference year 2009) (Continued)
30 J01XE01 Nitrofurantoin 5.4 0.26 4.1 0.76 € 8.7 0.43 6.7 0.85 € 62.07 % 59.99 % 61.45 %
Sum Top30 502.9 13.75 305.7 864.40 26.15 562.71 58.18 % 52.59 % 54.33 %
Sum all 83 agents 598.7 16.93 387.8 1,124.00 37.71 1,037.37 53.27 % 44.89 % 37.38 %
aPRISCUS agents which are potentially inappropriate at certain dose or release form
bThe PPR does include the 3,000 top-selling drugs. Several traded products with terazosin as agent are sold less frequently and therefore not included. The published amount of DDD of terazosin is lower than the















Table 2 Costs of surrogates for the elderly (Prices in €, Reference year 2009)






Costs per DDD of
surrogates in €
Total costs of
surrogates in Mio. €
Min Max Mean Min Max Mean
C02CA04 Doxazosin 0.38 51.4 Other antihypertensives: ACE inhibitors,
angiotensin receptor blockers, diuretics,
beta blocker, calcium channel blocker
ACE inhibitors 0.13 Angiotensin
receptor blockers
1.08 0.23 6.64 55.51 23.73
N06AA09 Amitriptyline 0.43 45.7 SSRIs, mirtazapine SSRIs 0.49 Mirtazapine 0.69 0.53 22.39 31.53 23.32
C07AA07 Sotalol 0.30 34.0 Beta blocker, amiodarone, propafenone beta blocker 0.30 Amiodarone 0.72 0.77 10.09 24.48 21.69
C01AA02 Acetyldigoxin 0.36 32.5 Beta blocker, diuretics, ACE inhibitors ACE inhibitors 0.13 Beta blocker 0.30 0.18 4.20 9.65 24.43






2.32 0.77 0.00 64.86 11.80
M01AH05 Etoricoxib 1.21 25.2 Paracetamol, weak opioids (codeine,
tramadol), Metamizole, weak NSAID,
antidepressants (long-acting tranquilizers,
tricyclic antidepressants, other non-
serotomergic monoamine oxidase





Paracetamol 0.49 Newer anti-
epileptics
4.03 3.90 12.35 101.56 16.50
N06AA12 Doxepin 0.54 24.2 SSRIs, mirtazapine SSRIs 0.49 Mirtazapine 0.69 0.53 11.86 16.70 12.94
G04BD08 Solifenacin 1.44 22.6 Trospium Trospium 1.05 Trospium 1.05 1.05 23.73 23.73 5.89






2.32 0.77 0.00 49.34 2.95




4.25 4.11 70.64 77.78 7.80
C04AD03 Pentoxifylline 0.48 15.0 ACE inhibitors (donepezil, galantamine,
rivastigmine), Memantine
Memantine 3.86 Acetylcholinesterase inhibitors 4.25 4.11 57.90 63.75 10.36
N05BA08 Bromazepam 0.58 14.9 Lorazepam, lormetazepam, short-acting
benzodiazepine & benzodiazepine
receptor agonists (zolpidem, zopiclone,
brotizolam, triazolam, zaleplon),
opipramol, mirtazapine, low-potency
neuroleptics (melperone & pipamperone)
Lormetazepam 0.42 Low-potency
neuroleptics
2.32 0.75 6.26 34.52 9.77
N06AA06 Trimipramine 0.74 14.6 SSRIs, mirtazapine SSRI 0.49 Mirtazapine 0.69 00.53 7.15 10.07 11.23
N05BA01 Diazepam 0.46 13.1 Lorazepam, lormetazepam, short-acting
benzodiazepine & benzodiazepine
receptor agonists (zolpidem, zopiclone,
brotizolam, triazolam, zaleplon), opipramol,
Lormetazepam 0.42 Low-potency
neuroleptics















Table 2 Costs of surrogates for the elderly (Prices in €, Reference year 2009) (Continued)
mirtazapine, low-potency neuroleptics
(melperone & pipamperone)
N05CD06 Lormetazepama 0.42 12.5 Valerian, sedative anti-depressants
(trazodone, mianserin, mirtazapine),
opipramol, zolpidem, low-potency
neuroleptics (melperone & pipamperone)
Valerian 0.00 Low-potency
neuroleptics
2.32 0.78 0.00 28.96 30.82
C02CA08 Terazosin 0.54 12.3 Other antihypertensives: ACE inhibitors
angiotensin receptor blockers, diuretics,
beta blocker , calcium channel blocker
(except nifedipine)
ACE inhibitors 0.13 Beta blocker 0.30 0.18 1.59 3.65 6.79
C02AC01 Clonidine 0.50 11.7 Other antihypertensives: ACE inhibitors,
angiotensin receptor blockers, diuretics,
beta blocker , calcium channel blocker
ACE inhibitors 0.13 Angiotensin receptor
blockers
1.08 0.23 1.51 12.64 61.64
C02LA01 Reserpine and
Diuretics
0.42 11.3 Other antihypertensives: ACE inhibitors,
angiotensin receptor blockers, diuretics,
beta blocker, calcium channel blocker
(except nifedipine)
ACE inhibitors 0.13 Beta blocker 0.30 0.18 1.46 3.35 2.24
C01BC04 Flecainide 1.18 9.7 Beta blocker, amiodarone Beta blocker 0.30 Amiodarone 0.72 0.30 2.88 6.98 9.87
G04BD04 Oxybutynin 0.95 9.3 Trospium Trospium 1.05 Trospium 1.05 1.05 9.77 9.77 2.69
M01AC06 Meloxicam 0.35 9.3 Paracetamol, weak opioids (codeine,
tramadol), metamizole, “weaker” NSAID
Paracetamol 0.49 Codeine 2.65 0.72 4.56 24.65 9.69
N06AB03 Fluoxetine 0.33 8.8 Other SSRIs (citalopram, paroxetine,
escitalopram, sertraline, escitalopram),
trazodone, mitrazapine
other SSRIs 0.51 Trazodone 1.44 0.56 4.50 12.67 8.71
M01AB01 Indometacin 0.46 8.7 Paracetamol, weak opioids (codeine,
tramadol), metamizole, “weaker” NSAID
Paracetamol 0.49 Codeine 2.65 0.72 4.26 23.06 4.60
C01AA08 Metildigoxin 0.32 8.4 Beta blocker, diuretics Diuretics 0.21 Beta blocker 0.30 0.26 1.76 2.49 2.06
M03BX07 Tetrazepam 0.96 8.3 Tolperisone, short-acting benzodiazepine
& benzodiazepine receptor agonists






0.71 Tolperisone 1.55 0.82 5.89 12.87 12.59




4.25 4.11 28.95 31.88 6.25
C08CA05 Nifedipinea 0.58 6.5 Other antihypertensives: ACE inhibitors,
angiotensin receptor blockers, diuretics,
beta blocker, calcium channel blocker
(except nifedipine)
ACE inhibitors 0.13 Beta blocker 0.30 0.18 0.84 1.93 1.19
M01AB11 Acemetacin 0.77 6.4 Paracetamol, weak opioids (codeine,
tramadol), metamizole, “weaker” NSAID















Table 2 Costs of surrogates for the elderly (Prices in €, Reference year 2009) (Continued)
M03BX01 Baclofen 0.87 6.0 Tolperisone, tizanidine Tizanidine 1.09 Tolperisone 1.55 1.45 6.54 9.30 4.91
J01XE01 Nitrofurantoin 0.76 5.4 Other antibiotics in accordance with
antibiogramm: cephalosporins,
cotrimoxazole, trimethoprim
Cotrimoxazole 1.77 Trimethoprim 2.79 2.33 9.56 15.07 2.16
Sum Top 30 502.9 325.93 810.03 430.46















average. However, these savings would be compensated for
by the 16 remaining agents, which lead to an average in-
crease of +160.7 %.
Discussion
To our knowledge, this is the first study to assess the re-
imbursement costs of PIM according to the PRISCUS
list in Germany from a SHI perspective. We conducted a
comprehensive analysis based on prescription data from
2009 in order to depict the prevalence of PIM in the
elderly in Germany and to quantify the economic impact
of prescriptions as well as the substitution costs for the
recommended medication.
The prevalence of PIM in the elderly
Our search yielded eight studies dealing with the preva-
lence of PIM in Germany, according to the PRISCUS list
[12–14, 17–21]. The present study is based on prescrip-
tion data in the ambulant stetting for all patients ≥65 years
of age in German SHI, and results in a prescription preva-
lence of 4.8 % in 2009. The investigations of Amann et al.
and Schubert et al. are most comparable regarding the
database. Amann et al. calculated a standardised preva-
lence of 28.3 % based on data on 800,000 insurees [17]. A
similar study design was chosen by Schubert et al. [13].
They used claims data from German health insurance pro-
viders to calculate a prevalence of 22.0 %. However, they
both analysed the prevalence at the patient level not at the
prescription level. Therefore, the comparison is limited.
The six remaining studies calculated prevalence based
on smaller patient samples and in different study settings.
The results lay between 16.6 % in an emergency depart-
ment [14] and 43 % in geriatric rehabilitation [12]. For
patients in nursing homes, a prevalence of 31.2 % was cal-
culated [18], while for elderly people living at home the
prevalence was lower at 18 % [19], 28.4 % [20] and 29.0 %
[21]. Thus, the prevalence of PIM in the elderly in Germany
is between one quarter and one third , but this depends on
the study setting, possible limitations concerning indication,
data collection, and the consideration of the limitations of
the PRISCUS list (dose dependency and release form).
Economic assessment of PIM and the recommended
substitution
A search of economic analyses showed that limited in-
formation is available. In total, 12 publications dealing
with the costs of PIM were identified, but none of them
considered German SHI. The studies were conducted in
the US [22–26], Ireland [7, 27, 28], Japan [8], Finland
[29], Saudi Arabia [30], and Switzerland [31]. They used
different lists and mostly calculated the costs of PIM at
the patient level [7, 8, 22, 25]. As our study addresses
the annual economic relevance of PIM for SHI in
Germany, only four studies from the US [24], Ireland
[27, 28], and Finland [29] that addressed the national
perspective are eligible for the comparison.
Bradley et al. analysed the PIM of patients >70 years of
age according to the STOPP criteria in Northern Ireland,
using data from the enhanced prescribing database of
the National Health Service [27]. In total, costs of €6.1
million in 2009/2010 were calculated. This equals 5.38 %
of total expenses on pharmaceuticals for people >70 years
of age in Northern Ireland. Another study of Ireland by
Cahir et al. published costs of €45.6 million for drug ingre-
dients, tax, and pharmacy surcharges in 2007, represent-
ing 9 % of the overall expenditure on pharmaceuticals in
people aged >70 years [28]. The calculation applying the
STOPP criteria was based on the pharmacy claims of the
National Shared Services Primary Care Reimbursement
Service of the Health Service Executive. In the third study,
Leikola et al. calculated reimbursement costs of €2.9
million for PIM medication to people >65 years of age in
Finland in 2007, using the criteria of Fick and Beers [29].
This represents 0.7 % of total drug reimbursement for
people aged >65 in Finland. The register-based cross-
sectional study used data from Finland’s social insurance
institution. The study from Fu et al., conducted in the US,
calculated total health care expenditures of US$7.2 billion
for community-dwelling patients exposed to PIM accord-
ing to the criteria of Fick and Beers [24]. For medication,
about 20 % of these costs were calculated. Consequently,
costs of approximately US$1.44 billion were calculated for
PIM in people >65 years of age in 2001 in the US.
In our study, the reimbursement costs of PIM were
€387.8 million. Thus, the total reimbursement costs for
PIM prescriptions in Germany are significantly higher
than those in Finland, Ireland, and Northern Ireland, but
lower than those in the US. The total sales of all propri-
etary mediclinical products in SHI were €28,499 million
[16]. Thus, the proportion of PIM sales to elderly pa-
tients represents 1.36 %. However, a comparison of this
number is hardly possible, as the studies from Finland,
Ireland, and Northern Ireland used sales to elderly pa-
tients as the reference figure.
In general, the comparability of our results with other
international studies is limited. First, different tools were
used to detect PIM: Bradley et al. and Cahir et al. ap-
plied the STOPP criteria, which contain 65 criteria sys-
tematised according to the physiological systems to
identify PIM [27, 28, 32]. The studies of Leikola et al.
and Fu et al. used the criteria of Fick and Beer from
2003, which partly consider the diagnoses or conditions
of patients [24, 29, 33]. In contrast to both tools, the
PRISCUS list considers neither the physiological system
nor diagnoses or conditions. Second, the lists were ap-
plied to different age groups: Bradley et al. calculated
costs for pharmaceutical expenses for patients ≥70 years
of age [27]. Our investigation covered prescriptions for
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patients ≥65 years of age. Third, different perspectives
on costs were used in the studies: Cahir et al. summed
the net ingredient costs, the value added tax, and the
pharmacist dispensing fee [28]. In our study, costs per
DDD are based on the sales data of each drug. Thus, the
different approaches make a comparison of costs of PIM
even more difficult.
Regarding PIM substitution, reimbursement costs are
about to rise, independent of the scenario. If all prescrip-
tions of PIM were substituted by the low-cost alternative,
the total costs would be €325.9 million. Substitution by the
most expensive alternative would lead to a total cost of
€810.0 million. This gap can be explained by the enormous
difference in the costs of the recommended therapeutic
alternatives. For example, there are several different al-
ternatives for etoricoxib (e.g., paracetamol, weak opi-
oids (codeine, tramadol), metamizol, anticonvulsants
(older anti-epileptics, newer anti-epileptics, neuromuscular
blocking agents)). The cheapest alternative to etoricoxib
(€1.21/DDD) is paracetamol (€0.49/DDD). The most ex-
pensive alternative is newer anti-epileptics at €4.03/DDD.
The difference in costs per DDD might result in enormous
cost differences in each scenario. By contrast, for solifena-
cin, which costs €1.43/DDD according to the PPR, the only
alternative according to the PRISCUS list is trospium, with
a cost of €1.05/DDD. Consequently, in both scenarios the
substitution of solifenacin will decrease the total costs.
Implication for SHI and future research
From a short-term economic perspective, there would
be little incentive for SHI to support the substitution of
PRISCUS agents. However, it has been shown that PIM
leads to ADE which in turn can cause inpatient costs
[14, 34, 35]. Furthermore, the application of PIM is dir-
ectly associated with an increased risk of acute hospital
admission [36–41]. Moreover, in many clinical cases
there may be no adequate substitute for a PIM. In these
cases, the discontinuation of the PIM without providing
a substitute will be the best choice from a clinical as well
as from an economical perspective. Thus, from a long-
term perspective, the additional costs of physician con-
sultation and hospitalisation due to ADEs caused by
PIM might decrease and compensate for the costs of
substituting the PRISCUS agents.
Our research revealed several aspects to be considered
in future research on PIM. The PRISCUS list was pub-
lished in 2010. Our study is based on data from 2009.
Thus, our study does not analyse the effect of the PRISCUS
list and possible changes in the prescription behaviour of
physicians in Germany, but serves as a reference for future
comparisons. Further research should investigate if and to
what extent prescription patterns and PIM costs have de-
veloped due to the PRISCUS list in order to show the influ-
ence and relevance for practical use.
Our investigation demonstrated that PIM is a rele-
vant topic in drug therapy in the elderly in Germany.
The elderly account for approximately 55 % of the sales
of the 30 top-selling PRISCUS agents. Similar percent-
ages were calculated for DDDs and prescriptions. The
proportion of sales, DDDs, and prescriptions to the eld-
erly is lower in all 83 agents of the PRISCUS list. The
decrease underlines that only some of the 83 PRISCUS
agents are really relevant. Thus, from an economic per-
spective and in terms of feasibility, a shorter PRISCUS
list might be more applicable for the daily health ser-
vice. However, the medical perspective has to be taken
into consideration as well. A short-list should also in-
clude those agents with the worst risk/benefit ratios for
the elderly.
Limitations
There are limitations to this study as a result of the
methods used. First, for several PIM the recommended
substitutions may not be clinically adequate in a majority
of clinical cases, while in other cases the recommended
substitution would lead to off-label use. For example,
herbal products, such as valerian, are often named as sur-
rogates for psycholeptics (zopiclone, zolpidem and lorme-
tazepam). From a medical perspective, however, it is
questionable if a highly effective sedative can be completely
substituted by herbal alternatives. Furthermore, valerian is
a non-refundable OTC and no costs occur by substituting
it. Consequently, in the low-cost scenario, approximately
€42 million can be "saved" by applying valerian. Second,
some PRISCUS agents are only potentially inappropriate, if
a certain dose is exceeded or a certain release form is ap-
plied. This was not taken into account, as the data set of
WIdO consisted of total prescriptions. Third, we only ana-
lysed the 30 top-selling drugs.
Another limitation is related to our applied scenar-
ios. In general, the scenarios assumed that a PIM
would be fully substituted by the cheapest, most
expensive, or mean costs. However, a complete substi-
tution might be unlikely in daily practice, which high-
lights the need for a calculation based on individual
patient data. In general, the proposed substitutions
have to be evaluated carefully by physicians. In some
cases, groups of potential surrogates include other
medication form the PRISCUS list. For example, the
recommended substitution of amitriptyline are SSRI.
However, the group of SSRI comprises PIM as well
e.g. fluoxetine. It remains unclear if in those cases
PIM might be substituted by another PIM as well. For
our study, we included all recommended surrogates.
Conclusions
This is the first study to assess the economic relevance
of PIM on the PRISCUS list in Germany from a SHI
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perspective. It was shown that PIM is present in Germany
and approximately 5 % of all prescriptions made to people
aged ≥65 years are potentially inappropriate. Moreover,
the reimbursement costs of PIM in the elderly account for
1.36 % of total sales to patients ≥65 years of age. The sub-
stitution of PRISCUS agents would lead to an increase in
costs independent of the chosen scenario. Thus, from a
short-term perspective, there is no incentive for SHI to
promote substitution. However, in the long-term, hospital-
isation and recurrent physician visits should be addressed.
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